Search results
Afrezza: Mild to serious side effects and how to manage them
Medical News Today· 1 day agoAfrezza (insulin human) is a brand-name inhaled insulin prescribed to manage blood sugars in adults...
AstraZeneca to present respiratory disease research at ATS 2024 By Investing.com
Investing.com· 3 days agoAstraZeneca (NASDAQ:AZN) is set to present new clinical and real-world data on its respiratory and...
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the 2024 American...
WTNH-TV New Haven· 6 days ago... of aderamastat (FP-025), A Selective MMP-12 Inhibitor, on Allergen-induced Airway Responses in...
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Yucaipa News Mirror· 2 days agoAmgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024. "With many of our innovative products delivering strong growth and promising new medicines advancing through ...
What to Know About Steroids for Treating Back Pain
Healthline· 2 days agoSteroids help reduce inflammation that can cause severe back pain, but steroids aren’t long-term solutions. Back pain can limit your mobility and...
An effective treatment for COVID-19 is underused - The Advocate-Messenger
The Danville Advocate-Messenger· 3 days agoA safe and effective medication designed to prevent mild-to-moderate COVID-19 infections from...
AJRCCM “Abstracts Issue” Showcases Research at the ATS 2024 International Conference
Newswise· 4 days agoMay 01, 2024– Get a sneak-peak at what’s coming up at the ATS 2024 later this month with today’s online release of the “American Thoracic Society International Conference Abstracts.” Published ...
Skin rash after eating asparagus? What could be behind it?
Weston Forum· 12 hours agoAn allergic reaction to asparagus is rare but possible. Asparagus season has begun. Allergists and...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Zacks· 2 days agoFree Report) reported first-quarter 2024 adjusted earnings of $3.96 per share, which beat the Zacks Consensus Estimate of $3.76. Total revenues of $7.45 billion beat the Zacks Consensus Estimate ...
